Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Benzodiazepine or Empathogen or [[:Category:Sulfonylureas|Sulfonylurea (second-generation)]]

Use the filters below to narrow your results.

generic:
brand:
None (25) · Dalmane (1) · Doral (1) · Glucotrol, Glucotrol XL (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-000002D7-QINU`"' Hypoglycemia is the central risk, especially in elderly and renally impaired patients (glipizide has shorter half-life than glyburide, which is one reason it is preferred in older adults). CYP2C9 substrate; weight gain typical. (1)
uses:
None (38) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-000002D8-QINU`"' (1)
starting dose:
None (38) · 0.25 mg (1) · 5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast (1)
preparations:
None (38) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets (1)
fda max:
None (38) · 10 mg/d (1) · 40 mg/d (IR; doses >15 mg given as divided BID); 20 mg/d (XL) (1)
routes:
None (38) · Oral (2)
onset:
None (38) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Within 30 minutes (IR) (1)
duration:
None (38) · 6 h (immediate-release); ~11 h (extended-release) (1) · ~12-24 hours (1)
halflife:
None (38) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2-5 hours'"`UNIQ--ref-000002D9-QINU`"' (1)
bioavailability:
None (38) · 80-90% oral (1) · ~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' (1)
pregnancy:
None (38) · Avoid; switch to insulin. Hypoglycemia in newborn reported.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)
legal:
None (38) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 40 results in range #1 to #40.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"